BG A3004
Alternative Names: BG-A3004Latest Information Update: 31 Mar 2026
At a glance
- Originator BeOne Medicines
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Skin disorders
Most Recent Events
- 19 Mar 2026 Phase-I clinical trials in Skin disorders in China (SC) (NCT07412691)
- 10 Mar 2026 BeOne Medicines plans a phase-I trial for Skin-disorders (In adults) (SC) (NCT07412691)
- 17 Feb 2026 Preclinical trials in Skin disorders in Switzerland (SC)